4 Healthcare Stock Stories for the End Of The Trading Week

Gilead Sciences (NASDAQ:GILD): Closing price $48.94

Gilead has provided an update on ION-1, its Phase 3 clinical trial examining a once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin for 12 or 24 weeks, among 800 treatment-naïve genotype 1 patients suffering from hepatitis C virus  infection. A planned evaluation by the study’s Data and Safety Monitoring Board of safety data from 200 patients in all four arms and of SVR4 rates (sustained virologic response four weeks after completion of therapy) from 100 patients in the two 12-week duration arms, concluded that the trial should continue without modification. This recommendation is calculated upon the observed SVR4 rates surpassing the predefined threshold of 60 percent and the absence of significant safety problems. Enrollment of the remaining 600 patients in ION-1 is now underway.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GILD

Insmed Incorporated (NASDAQ: INSM): Closing price $7.49

On Thursday, Insmed said that Arikace, its Iiposomal amikacin for inhalation, has been granted orphan drug designation from the FDA’s Office of Orphan Products Development for the treatment of infections caused by non-tuberculous mycobacteria. Insmed is a biopharmaceutical firm concentrated on the development and commercialization of inhaled therapies for patients struggling with serious lung diseases in orphan indications that are often life-threatening.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

INSM

Pfizer (NYSE:PFE): Closing price $28.86

KineMed reported the renewal of a non-exclusive research partnership with Pfizer to move forward novel approaches towards metabolic disease, and in particular Type II Diabetes. The collaboration will utilize KineMed’s unique dynamic proteomics tech platform to map out the impact of potential drug candidates upon specific metabolic pathways.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Cell Therapeutics (NASDAQ:CTIC): Closing price $1.15

The firm announced Thursday that it has entered into a loan agreement with Hercules Technology Growth Capital, providing for a senior secured term loan of as much as $15 million. The initial $10 million of the term loan was funded at closing, and the remaining $5 million is available at CTI’s option at any time from November 30th through December 15, 2013, subject to certain conditions. President and Chief Executive James A. Bianco, M.D. of CTI commented that ”the proceeds from this loan facility are expected to provide us with additional operating capital to advance our Phase 3 clinical development programs. Our primary focus remains on our near-term strategic goals of completing the Phase 3 studies of pacritinib in patients with myelofibrosis, driving adoption of Pixuvri in Europe and securing non-equity based operating capital through strategic partnerships.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CTIC

Don’t Miss: Is UnitedHealth Suddenly a Dangerous Investment?